About Zinc finger protein 83
Zinc finger protein 83 (ZNF83) is a protein
from Homo sapiens identified by UniProt accession
P51522, 516 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | Zinc finger protein 83 |
| UniProt accession | P51522 |
| Gene | ZNF83 |
| Organism | Homo sapiens |
| Length | 516 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (28)
Diseases linked to this target (Open Targets).
- hair colour measurement · score 0.24
- Red cell distribution width · score 0.17
- ulcerative colitis · score 0.07
- neoplasm · score 0.07
- cancer · score 0.02
- urinary bladder carcinoma · score 0.02
- psoriasis · score 0.01
- ovarian carcinoma · score 0.01
- hepatocellular carcinoma · score 0.01
- squamous cell carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P51522-F1 | alphafold | PREDICTED | 75.51 | — |
Amino-acid sequence (516 residues)
MHGRKDDAQK QPVKNQLGLN PQSHLPELQL FQAEGKIYKY DHMEKSVNSS SLVSPPQRIS STVKTHISHT YECNFVDSLF TQKEKANIGT EHYKCSERGK AFHQGLHFTI HQIIHTKETQ FKCDICGKIF NKKSNLASHQ RIHTGEKPYK CNECGKVFHN MSHLAQHRRI HTGEKPYKCN ECGKVFNQIS HLAQHQRIHT GEKPYKCNEC GKVFHQISHL AQHRTIHTGE KPYECNKCGK VFSRNSYLVQ HLIIHTGEKP YRCNVCGKVF HHISHLAQHQ RIHTGEKPYK CNECGKVFSH KSSLVNHWRI HTGEKPYKCN ECGKVFSHKS SLVNHWRIHT GEKPYKCNEC GKVFSRNSYL AQHLIIHAGE KPYKCDECDK AFSQNSHLVQ HHRIHTGEKP YKCDECGKVF SQNSYLAYHW RIHTGEKAYK CNECGKVFGL NSSLAHHRKI HTGEKPFKCN ECGKAFSMRS SLTNHHAIHT GEKHFKCNEC GKLFRDNSYL VRHQRFHAGK KSNTCN
Explore Zinc finger protein 83 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets